Publications by authors named "Mariam Fanous"
Article Synopsis
- Checkpoint blockade therapies, particularly anti-PD-1 antibodies, show high effectiveness in Hodgkin lymphoma but low response rates in non-Hodgkin lymphomas like chronic lymphocytic leukemia (CLL).
- Combining anti-PD-1 or PD-L1 therapies with avadomide, a cereblon E3 ligase modulator, enhances anti-CLL effects by stimulating immune responses and T-cell activation.
- Clinical findings indicate that avadomide treatment leads to increased PD-L1 expression on T cells and better immune signaling in B-cell cancer patients, highlighting the need to boost T-cell inflammation for effective therapy.
